Search Results

You are looking at 1 - 10 of 270 items for :

  • "ovarian cancer" x
Clear All
Full access

Robert J. Morgan Jr., Ronald D. Alvarez, Deborah K. Armstrong, Barry Boston, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi J. Gray, Perry W. Grigsby, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Russell J. Schilder, Julian C. Schink, Nelson Teng and Theresa L. Werner

O varian neoplasms consist of several histopathologic entities, and treatment depends on the specific tumor type. Epithelial ovarian cancer comprises most malignant ovarian neoplasms (∼ 80%) 1 ; however, other less-common pathologic subtypes must

Full access

Robert J. Morgan Jr, Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Kian Behbakht, Lee-may Chen, Larry Copeland, Marta Ann Crispens, Maria DeRosa, Oliver Dorigo, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Sanja Percac-Lima, Mario Pineda, Steven C. Plaxe, Matthew A. Powell, Elena Ratner, Steven W. Remmenga, Peter G. Rose, Paul Sabbatini, Joseph T. Santoso, Theresa L. Werner, Jennifer Burns and Miranda Hughes

Ovarian neoplasms consist of several histopathologic entities; treatment depends on the specific tumor type. 1 Epithelial ovarian cancer comprises the majority of malignant ovarian neoplasms (about 90%) 2 – 4 ; however, other less common pathologic

Full access

Deborah K. Armstrong

Most patients with ovarian cancer are diagnosed with advanced-stage cancer. Debulking surgery followed by chemotherapy is recommended. The standard front-line regimen is 6 cycles of paclitaxel plus carboplatin, with docetaxel a reasonable

Full access

Ernest S. Han and Mark Wakabayashi

M ore than 21,000 women are estimated to be diagnosed with epithelial ovarian cancer in the United States in 2010, and an estimated 13,850 will die of the disease. 1 Of all gynecologic cancers, ovarian cancer is the most common cause of death. 1

Full access

Maurie Markman

to help oncologists determine the statistically defined likelihood the patient will experience a more- or less-favorable outcome (prognostic testing). In ovarian cancer, validated and useful prognostic tests include tumor grade, surgical stage, volume

Full access

Deborah K. Armstrong

The NCCN Guidelines for Ovarian Cancer include recommendations for a broad range of histologic subtypes of this malignancy, and recommendations for use of oral poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors. As maintenance therapy

Full access

Robert J. Morgan Jr, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Matthew A. Powell, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Julian C. Schink, Nelson Teng, Theresa L. Werner, Mary A. Dwyer and Miranda Hughes

: Integrate into professional practice the updates to NCCN Guidelines for Ovarian Cancer Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Ovarian Cancer NCCN Categories of Evidence and Consensus Category

Full access

Robert J. Morgan, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Mariana Castells, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Russell J. Schilder, Julian Schink, Nelson Teng, Theresa L. Werner, Miranda Hughes and Mary A. Dwyer

NCCN Guidelines Insights : Ovarian Cancer,Version 3.2012 Version 3.2012 © National Comprehensive Cancer Network, Inc. 2012, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the

Full access

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019

Featured Updates to the NCCN Guidelines

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Jonathan S. Berek, Lee-may Chen, Mihaela Cristea, Marie DeRosa, Adam C. ElNaggar, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Angela Jain, Carolyn Johnston, Charles A. Leath III, Joyce Liu, Haider Mahdi, Daniela Matei, Michael McHale, Karen McLean, David M. O’Malley, Richard T. Penson, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Paul Sabbatini, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns and Anita M. Engh

able to: Integrate into professional practice the updates to the NCCN Guidelines for Ovarian Cancer Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Ovarian Cancer Disclosure of Relevant Financial

Full access

Matthieu Picard, Ursula A. Matulonis and Mariana Castells

Ovarian cancer is the leading cause of death among gynecologic malignancies and ranks fifth in overall cancer-related mortality among women in the United States. 1 Chemotherapy, particularly with a taxane and platinum combination, is key to